<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2017.02265</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Leishmania infantum</italic> Induces the Release of sTREM-1 in Visceral Leishmaniasis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Bomfim</surname> <given-names>Lays G. S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/493890/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Magalh&#x000E3;es</surname> <given-names>Lucas S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/493919/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Santos-Filho</surname> <given-names>Marcello A. A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peres</surname> <given-names>Nalu T. A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/285290/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Corr&#x000EA;a</surname> <given-names>Cristiane B.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tanajura</surname> <given-names>Diego M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/471372/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Silva</surname> <given-names>Angela M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lipscomb</surname> <given-names>Michael W.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Borges</surname> <given-names>Val&#x000E9;ria M.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/50580/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Jesus</surname> <given-names>Am&#x000E9;lia R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/497134/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Almeida</surname> <given-names>Roque P.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/457026/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>de Moura</surname> <given-names>Tatiana R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/462040/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laborat&#x000F3;rio de Biologia Molecular-Hospital Universit&#x000E1;rio, Universidade Federal de Sergipe-Aracaju</institution>, <addr-line>Sergipe</addr-line>, <country>Brazil</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Biology, Howard University</institution>, <addr-line>Washington, DC</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Instituto Gon&#x000E7;alo Moniz, Funda&#x000E7;&#x000E3;o Oswaldo Cruz</institution>, <addr-line>Salvador</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Debora Decote-Ricardo, Universidade Federal Rural do Rio de Janeiro, Brazil</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Marisa Mariel Fernandez, University of Buenos Aires, Instituto de Estudios de la Inmunidad Humoral (IDEHU) (CONICET-UBA), Argentina; Herbert Leonel de Matos Guedes, Universidade Federal do Rio de Janeiro, Brazil; Elisangela Oliveira De Freitas, University of S&#x000E3;o Paulo, Brazil</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Tatiana R. de Moura <email>tmoura.ufs&#x00040;gmail.com</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Microbiology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>2265</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>08</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Bomfim, Magalh&#x000E3;es, Santos-Filho, Peres, Corr&#x000EA;a, Tanajura, Silva, Lipscomb, Borges, Jesus, Almeida and de Moura.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Bomfim, Magalh&#x000E3;es, Santos-Filho, Peres, Corr&#x000EA;a, Tanajura, Silva, Lipscomb, Borges, Jesus, Almeida and de Moura</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract><p>Visceral leishmaniasis (VL) is a systemic transmissible disease that remains to be a major global health problem. The inflammatory response during VL is characterized by the release of several cytokines and other pro-inflammatory mediators. Triggering Receptor Expressed on Myeloid Cells (TREM) are a group of evolutionarily conserved membrane-bound surface receptors expressed on neutrophils and monocytes. Engagement of TREM-1 directs intracellular signaling events that drive cytokine production, degranulation, and phagocytosis. In certain inflammatory-associated diseases, TREM-1 can also be found as a soluble form (sTREM-1), which can negatively regulate TREM-1 receptor signaling. In these studies, we now find that high levels of circulating sTREM-1 correlate directly with VL disease severity. In particular, high levels of sTREM-1 were observed in non-survivor VL patients. Furthermore, these levels of sTREM-1 positively correlated with liver size and negatively correlated with leukocyte counts and hemoglobin concentration. Moreover, we found that neutrophils exposure <italic>in vitro</italic> to <italic>Leishmania infantum</italic> modulates TREM-1, DAP12, and IL-8 gene expression, while also increasing release of sTREM-1. Finally, results revealed that higher sTREM-1 levels are associated with increasing parasite ratio. Taken together, these studies suggest that <italic>L. infantum</italic> may modulate TREM-1 in neutrophils and high levels of this molecule is associated with severe VL.</p></abstract>
<kwd-group>
<kwd>visceral leishmaniasis</kwd>
<kwd><italic>Leishmania infantum</italic></kwd>
<kwd>neutrophils</kwd>
<kwd>sTREM-1</kwd>
<kwd>TREM-1</kwd>
</kwd-group>
<contract-num rid="cn001">460743/2014-7</contract-num>
<contract-num rid="cn001">552721/2011-5</contract-num>
<contract-num rid="cn002">019.203.02712/2009-8</contract-num>
<contract-num rid="cn003">032/2010</contract-num>
<contract-num rid="cn004">SC2GM103741</contract-num>
<contract-num rid="cn005">W911NF-14-1-0123</contract-num>
<contract-num rid="cn006">1428768</contract-num>
<contract-sponsor id="cn001">Conselho Nacional de Desenvolvimento Cient&#x000ED;fico e Tecnol&#x000F3;gico<named-content content-type="fundref-id">10.13039/501100003593</named-content></contract-sponsor>
<contract-sponsor id="cn002">Funda&#x000E7;&#x000E3;o de Apoio &#x000E0; Pesquisa e &#x000E0; Inova&#x000E7;&#x000E3;o Tecnol&#x000F3;gica do Estado de Sergipe<named-content content-type="fundref-id">10.13039/501100005671</named-content></contract-sponsor>
<contract-sponsor id="cn003">Coordena&#x000E7;&#x000E3;o de Aperfei&#x000E7;oamento de Pessoal de N&#x000ED;vel Superior<named-content content-type="fundref-id">10.13039/501100002322</named-content></contract-sponsor>
<contract-sponsor id="cn004">Foundation for the National Institutes of Health<named-content content-type="fundref-id">10.13039/100000009</named-content></contract-sponsor>
<contract-sponsor id="cn005">U.S. Department of Defense<named-content content-type="fundref-id">10.13039/100000005</named-content></contract-sponsor>
<contract-sponsor id="cn006">National Science Foundation<named-content content-type="fundref-id">10.13039/100000001</named-content></contract-sponsor>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="29"/>
<page-count count="8"/>
<word-count count="5171"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Visceral Leishmaniasis (VL), a neglected tropical disease in the Americas, is caused by the <italic>Leishmania infantum</italic> parasite. VL exhibits a broad spectrum of clinical manifestations that vary from asymptomatic to the classic pathological disease state. The latter can be characterized by long-term fever, hepatosplenomegaly, anemia, leucopenia, thrombocytopenia, and weight loss. If not treated in a timely manner, this classic pathological disease can result in severe morbidity and/or cause mortality (Sampaio et al., <xref ref-type="bibr" rid="B23">2010</xref>).</p>
<p>Neutrophils, as the most abundant leukocytes in humans, serve a pivotal role in combating and defending against invading pathogens. However, their role in VL is poorly understood. Recently, it was shown that circulating neutrophils were highly activated in patients with VL in Ethiopia, but that their pro-inflammatory effector functions were impaired (Yizengaw et al., <xref ref-type="bibr" rid="B29">2016</xref>). Several receptors displayed on the surface of neutrophils can recognize foreign molecules and serve to initiate pro-inflammatory response against microorganisms. One particularly novel family of evolutionary conserved receptors are the Triggering Receptor Expressed on Myeloid Cells (TREM) molecules, which are expressed in neutrophils, macrophages, and in subsets of monocytes (Bouchon et al., <xref ref-type="bibr" rid="B5">2000</xref>).</p>
<p>In particular, TREM-1 expression can be directly induced by engagement with microbial products. Interaction with cognate ligands has shown to trigger release of IL-8, TNF-&#x003B1;, IL-1&#x003B2;, MIP-1&#x003B1;, and MCP-1 pro-inflammatory cytokines (Bouchon et al., <xref ref-type="bibr" rid="B5">2000</xref>; Arts et al., <xref ref-type="bibr" rid="B3">2013</xref>). Interestingly, TREM-1 can also be found in its soluble form (sTREM-1), which seems to negatively regulate TREM-1 receptor signaling (Gibot et al., <xref ref-type="bibr" rid="B13">2004b</xref>; Klesney-Tait et al., <xref ref-type="bibr" rid="B15">2006</xref>). Although the origin of native soluble TREM-1 remains controversial, the potential role of sTREM-1 in regulating infectious diseases has been extensively investigated (Gibot et al., <xref ref-type="bibr" rid="B12">2004a</xref>; Cao et al., <xref ref-type="bibr" rid="B6">2017</xref>). Many studies point to the potential use of sTREM-1 as a biomarker for infectious and non-infectious inflammatory diseases, such as sepsis (Gibot and Cravoisy, <xref ref-type="bibr" rid="B11">2004</xref>) and rheumatoid arthritis (Molad et al., <xref ref-type="bibr" rid="B16">2015</xref>). In cases of VL, biomarkers that can adequately assess disease severity would improve the clinical monitoring of patients.</p>
<p>In the present study, we investigated sTREM-1 serum levels in VL patients and membrane-bound TREM-1 receptor expression on neutrophils exposed to <italic>L. infantum</italic>. Our results show that high levels of sTREM-1 are present in VL patients, with the highest levels in non-survivors of the disease. We found that sTREM-1 positively correlated with increased liver size and negatively correlated with leukocyte counts and hemoglobin concentration. Corroborative <italic>in vitro</italic> studies showed that <italic>L. infantum</italic> infections into neutrophils directly induced TREM-1, DAP12, and IL-8 gene expression. Additionally, there was a significant increase in sTREM-1 release and concomitant decrease of membrane-bound TREM-1 from these infected neutrophils. Taken together, the results suggest an important role of sTREM-1 and presents a case for use as a biomarker to evaluate disease severity.</p>
</sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and methods</title>
<sec>
<title>Ethics statement</title>
<p>This study was approved by the Ethics Committee of the University Hospital of the Federal University of Sergipe (CAAE-53366916.8.0000.5546). All clinical investigations were conducted with informed consent obtained from all participants or legal guardians, in accordance with the Declaration of Helsinki.</p>
</sec>
<sec>
<title>Subjects and sample collection</title>
<p>The study assessed individuals in five groups: (1) patients with classical VL manifestation before leishmaniasis chemotherapy, day 0 (D0) (<italic>n</italic> &#x0003D; 21); (2) patients with classical VL manifestation 30 days after treatment (D30) (<italic>n</italic> &#x0003D; 16); (3) patients with severe VL (SVL) before leishmaniasis chemotherapy (<italic>n</italic> &#x0003D; 10); (4) DTH&#x0002B; are subjects with positive delayed type hypersensitivity (DTH) skin test, who did not develop VL (<italic>n</italic> &#x0003D; 10); (5) healthy controls (HC) are subjects without infectious or other inflammatory diseases (<italic>n</italic> &#x0003D; 17). The patients were recruited at the Reference Center at the University Hospital in Sergipe, Brazil, diagnosed with VL, and the patients with SVL were classified based on clinical score described by Sampaio et al. (<xref ref-type="bibr" rid="B23">2010</xref>). Furthermore, these individuals were validated by a new more complete criteria that has both higher sensitivity and specificity (Costa et al., <xref ref-type="bibr" rid="B8">2016</xref>). Blood was collected from all subjects. Sera was processed and stored at &#x02212;80&#x000B0;C until use. For the <italic>in vitro</italic> experiments, peripheral blood from healthy human donors was used.</p>
</sec>
<sec>
<title><italic>Leishmania infantum</italic> parasites</title>
<p>The parasite <italic>L. infantum</italic> (MHOM/BR/2010/LVHSE49) used in this study was obtained from a patient with VL in 2010 in Aracaju, Brazil. The parasite was isolated by bone marrow puncture (before the start of the therapeutic regimen) and inoculated into Novy, Mac Neal and Nicole (NNN) and Schneider&#x00027;s Insect medium (Gibco, NY, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich Co., MO, USA) and 1% penicillin/streptomycin. Parasites were kept in frozen stocks after only one passage in culture to limit expansion of mutant strains. <italic>Leishmania</italic> isolates were expanded in supplemented Schneider&#x00027;s medium at 24&#x000B0;C. Promastigotes were examined daily using light microscopy to determine growth curves.</p>
</sec>
<sec>
<title>Neutrophils culture and exposure to <italic>L. infantum</italic></title>
<p>Neutrophils were isolated from the peripheral blood of healthy human donors using Polymorphprep&#x02122; (Axis-Shield). After isolation, neutrophils were re-suspended in RPMI 1640 culture medium (Gibco, Carsbad, CA, USA) supplemented with 1% nutridoma and 1% penicillin/streptomycin. The cells were diluted to a concentration of 2.5 &#x000D7; 10<sup>6</sup> cells/ml and plated into 96-well plates in a total volume of 200 &#x003BC;l of complete RPMI-1640 medium (5 &#x000D7; 10<sup>5</sup> cells/well). For infection, neutrophils were exposed to <italic>L. infantum</italic> promastigotes in the stationary phase (MHOM/BR/2010/LVHSE49) at ratios of 1:1, 5:1, or 10:1 (parasites:neutrophil). Cells and parasites were then cultured for 30 min or for 3, 6, or 9 h at 37&#x000B0;C in 5% CO<sub>2</sub>. After the exposure period, supernatants were collected and stored at &#x02212;80&#x000B0;C until use.</p>
</sec>
<sec>
<title>Quantitative real-time polymerase chain reaction (qPCR)</title>
<p>To evaluate gene expression after neutrophil exposure to <italic>Leishmnia</italic>, cells were harvested and resuspended in Trizol reagent (Life Technologies) prior to total RNA extraction. Total RNA was reverse transcribed into single-stranded cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For real time PCR reactions, the Applied Biosystems TaqMan Gene Expression Master Mix and Gene Expression Assay kits were used (assay IDs TREM-1: Hs00218624-m1, DAP12: Hs00182426_m1, IL-8: Hs00174103_m1). Expression levels of the target transcripts were calculated by the comparative Ct method (2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> formula) after normalization with the house-keeping gene GAPDH (Hs99999905_m1).</p>
</sec>
<sec>
<title>Flow cytometric analysis for TREM-1 detection on the neutrophils surface</title>
<p>To evaluate the surface expression of TREM-1 on neutrophils, <italic>L. infantum</italic> parasites were pre-labeled with fluorescent probe CellTracker&#x02122; Violet BMQC (Life Technologies) before adding to neutrophils, following the protocol previously described (Dagley et al., <xref ref-type="bibr" rid="B9">2015</xref>). After 30 min or 3 h, exposed cells were washed and incubated with anti-CD354/TREM-1 (Biolegend). Data was acquired using the FACS CANTO II (BD Biosciences) and analyzed using FlowJo v10.0 software (Tree Star).</p>
</sec>
<sec>
<title>Measurement of sTREM-1 by ELISA</title>
<p>The levels of sTREM-1 in the serum and cell-free culture supernatants were measured by specific enzyme-linked immunosorbent assay (ELISA) kits (DuoSet, R&#x00026;D Systems, Abingdon, UK). The absorbance at 450 nm was measured using a microplate reader (Epoch, BioTek, Luzern, Switzerland), with a wavelength correction set at 570 nm to subtract background. A standard curve was generated for each set of samples assayed using manufacturer&#x00027;s recommended protocol.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Median and interquartile ranges were used as measures of central tendency for the <italic>ex vivo</italic> analyses. Mean and standard errors were used to display data from the <italic>in vitro</italic> experiments. Differences between two groups were calculated using the Student <italic>t</italic>-Test, Mann&#x02013;Whitney <italic>U-</italic>test, or the Kruskal-Wallis test with the Dunn. Multiple comparisons or linear trend analysis post-tests (more than 2 groups) used Friedman with Bonferroni post-test and One-Way ANOVA. Correlations were tested using Spearman and Pearson ranks. Differences with <italic>p</italic> &#x0003C; 0.05 were considered statistically significant. Analyses were performed using Prism 6.0 software (GraphPad).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>High serum levels of sTREM-1 was associated with VL severity</title>
<p>Serum levels of sTREM-1 were measured in patients with distinct VL clinical forms. Results revealed higher levels of sTREM-1 in severe VL (SVL) patients compared to all groups (<italic>P</italic> &#x0003C; 0.05) (Figure <xref ref-type="fig" rid="F1">1A</xref>). The median level of sTREM-1 among SVL patients (377.9 pg/ml) was about 7-fold higher than that among patients with classic VL D0 (48.77 pg/ml). This was 6.45-fold higher than classical VL D30 and 5.61-fold higher than DTH&#x0002B;. Interestingly, all non-survivor SVL patients showed sTREM-1 levels above 300 pg/ml. Furthermore, 90% of the SVL group showed levels above the 99.4 pg/ml found within the control group. In fact, by use the receiver-operating characteristic (ROC) curve, serum-sTREM-1 levels had 90% sensitivity and 85.7% specificity for differentiating patients with classical VL D0 from those SVL, with the cut-off value of 120.3 pg/ml and likelihood ratio of 6.3 (area under the ROC curve, 0.9524; <italic>P</italic> &#x0003D; 0.0001), authenticating its clinical utility as a biomarker to discriminate the severity form (Figure <xref ref-type="fig" rid="F1">1B</xref>). To investigate whether increased sTREM-1 levels are associated with disease, we correlated sTREM-1 levels with liver enlargement, leukocyte counts and hemoglobin concentration (Figure <xref ref-type="fig" rid="F1">1C</xref>). Liver enlargement, which is the classical manifestation of VL, positively correlated with circulating sTREM-1. Leukocyte counts and hemoglobin concentration negatively correlated with sTREM-1. Interestingly, SVL patients showed high sTREM-1 levels and lower counts of lymphocytes and neutrophils (Table <xref ref-type="table" rid="T1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>sTREM-1 serum levels were associated with severe visceral leishmaniasis (SVL). <bold>(A)</bold> sTREM-1 measured in serum samples from classical VL patients before (VL D0; green; <italic>n</italic> &#x0003D; 21) and after treatment (VL D30; blue; <italic>n</italic> &#x0003D; 16); patients with severe VL (SLV) that survived (purple; <italic>n</italic> &#x0003D; 6) and those that died (red; <italic>n</italic> &#x0003D; 4); DTH&#x0002B; subjects (black; <italic>n</italic> &#x0003D; 10). Shaded region represents median and interquartile range values of sTREM-1 from 17 healthy endemic controls to serve as reference (<sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05, <sup>&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.01, <sup>&#x0002A;&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.001, by ANOVA and Bonferroni post-test). <bold>(B)</bold> A receiver operating characteristic (ROC) curve was generated for discriminates the levels of sTREM-1 between patients with classical VL from patients with severe VL (area under the ROC curve [AUC], 0.9524; <italic>P</italic> &#x0003D; 0.0001). <bold>(C)</bold> Correlations between serum sTREM-1 levels with liver size, leukocyte counts and hemoglobin levels in patients with VL and SVL. Dotted lines on the X-axis represent the median value of sTREM-1 of the healthy endemic controls. Dotted lines on Y-axis indicate cell count of respective clinical parameter. Shaded region designate individuals simultaneously displaying sTREM-1 levels below the medians and clinical parameters. Correlations were analyzed using Spearman and Pearson ranks.</p></caption>
<graphic xlink:href="fmicb-08-02265-g0001.tif"/>
</fig>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Clinical data of patients with classical visceral leishmaniasis (VL) and severe (SVL) in the pre-treatment phase.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Parameters</bold></th>
<th valign="top" align="center"><bold>Patients with VL (D0) (<italic>n</italic> &#x0003D; 21)</bold></th>
<th valign="top" align="center"><bold>Patients with SVL (<italic>n</italic> &#x0003D; 10)</bold></th>
<th valign="top" align="center"><bold>Value de <italic>p</italic></bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gender (M/F)</td>
<td valign="top" align="center">11/10</td>
<td valign="top" align="center">9/1</td>
<td valign="top" align="center">&#x02013;</td>
</tr>
<tr>
<td valign="top" align="left">Age</td>
<td valign="top" align="center">17.43 &#x000B1; 16.77</td>
<td valign="top" align="center">26.80 &#x000B1; 21.97</td>
<td valign="top" align="center">0.1986</td>
</tr>
<tr>
<td valign="top" align="left">Spleen (cm)</td>
<td valign="top" align="center">8.094 &#x000B1; 3.908</td>
<td valign="top" align="center">8.167 &#x000B1; 3.162</td>
<td valign="top" align="center">0.9448</td>
</tr>
<tr>
<td valign="top" align="left">Liver (cm)</td>
<td valign="top" align="center">5.417 &#x000B1; 3.611</td>
<td valign="top" align="center">5.611 &#x000B1; 1.167</td>
<td valign="top" align="center">0.3487</td>
</tr>
<tr>
<td valign="top" align="left">Leucocytes/mm<sup>3</sup></td>
<td valign="top" align="center">3,155 &#x000B1; 1,542</td>
<td valign="top" align="center">1,599 &#x000B1; 640.1</td>
<td valign="top" align="center">0.0074<xref ref-type="table-fn" rid="TN2"><sup>&#x0002A;&#x0002A;</sup></xref></td>
</tr>
<tr>
<td valign="top" align="left">Neutrophils/mm<sup>3</sup></td>
<td valign="top" align="center">1,059 &#x000B1; 614.0</td>
<td valign="top" align="center">522.3 &#x000B1; 277.1</td>
<td valign="top" align="center">0.0191<xref ref-type="table-fn" rid="TN1"><sup>&#x0002A;</sup></xref></td>
</tr>
<tr>
<td valign="top" align="left">Eosinophils/mm<sup>3</sup></td>
<td valign="top" align="center">19.49 &#x000B1; 39.04</td>
<td valign="top" align="center">3.44 &#x000B1; 6.579</td>
<td valign="top" align="center">0.1213</td>
</tr>
<tr>
<td valign="top" align="left">Lymphocytes/mm<sup>3</sup></td>
<td valign="top" align="center">1,763 &#x000B1; 1,362</td>
<td valign="top" align="center">808.0 &#x000B1; 634.0</td>
<td valign="top" align="center">0.0425<xref ref-type="table-fn" rid="TN1"><sup>&#x0002A;</sup></xref></td>
</tr>
<tr>
<td valign="top" align="left">Monocytes/mm<sup>3</sup></td>
<td valign="top" align="center">288.0 &#x000B1; 233.4</td>
<td valign="top" align="center">203.9 &#x000B1; 115.7</td>
<td valign="top" align="center">0.3433</td>
</tr>
<tr>
<td valign="top" align="left">Hemoglobin (g/dL)</td>
<td valign="top" align="center">8.603 &#x000B1; 1.821</td>
<td valign="top" align="center">7.479 &#x000B1; 1.063</td>
<td valign="top" align="center">0.0979</td>
</tr>
<tr>
<td valign="top" align="left">Hematocrit (%)</td>
<td valign="top" align="center">26.83 &#x000B1; 5.398</td>
<td valign="top" align="center">23.20 &#x000B1; 3.496</td>
<td valign="top" align="center">0.0770</td>
</tr>
<tr>
<td valign="top" align="left">Platelets/mm<sup>3</sup></td>
<td valign="top" align="center">123,995 &#x000B1; 83,215</td>
<td valign="top" align="center">85,566 &#x000B1; 62,118</td>
<td valign="top" align="center">0.2294</td>
</tr>
<tr>
<td valign="top" align="left">AST (U/L)</td>
<td valign="top" align="center">142.4 &#x000B1; 123.2</td>
<td valign="top" align="center">143.4 &#x000B1; 133.6</td>
<td valign="top" align="center">0.8262</td>
</tr>
<tr>
<td valign="top" align="left">ALT (U/L)</td>
<td valign="top" align="center">85.5 &#x000B1; 79.90</td>
<td valign="top" align="center">1,082 &#x000B1; 3,302</td>
<td valign="top" align="center">0.2051</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Values express the mean &#x000B1; standard deviation. The p-value expresses the statistical difference for clinical outcomes between the two groups of VL patients, analyzed using Student&#x00027;s T-test for parametric data and Mann-Whitney test for non-parametric data</italic>.</p>
<fn id="TN1">
<label>&#x0002A;</label>
<p><italic>P &#x0003C; 0.05;</italic></p></fn>
<fn id="TN2">
<label>&#x0002A;&#x0002A;</label>
<p><italic>P &#x0003C; 0.01</italic>.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Gene expression of TREM-1, DAP12, and IL-8 is increased in neutrophils exposed to <italic>L. infantum</italic></title>
<p>Since VL is largely caused by the <italic>L. infantum</italic> strain, we next investigated whether exposure can modulate TREM-1 expression in neutrophils. Upon infection of peripheral blood-isolated neutrophils with the parasites for 30 min <italic>in vitro</italic>, gene expression of TREM-1, DAP12, and IL-8 was found to be higher compared to unexposed neutrophils (Figure <xref ref-type="fig" rid="F2">2A</xref>). TREM-1 expression among exposed neutrophils was 2.5-fold higher than the unexposed neutrophils. Similarly, DAP12 and IL-8 expression among exposed neutrophil were higher, with 2.0- and 3.0-fold, respectively, than the unexposed group.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><italic>Leishmania infantum</italic> modulated TREM-1 in human neutrophils. <bold>(A)</bold> Gene expression of TREM-1, DAP12, and IL-8 in neutrophils upon exposure to <italic>L. infantum</italic>. Neutrophils from healthy donors were exposed to <italic>L. infantum</italic> at a 5:1 ratio (parasites:cell). Control group was unexposed neutrophils. Relative gene expression was determined after 30 min of exposure. Bars represent the mean &#x000B1; standard error of 3 independent experiments with 7 donors (<sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05; <sup>&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.01, by Student&#x00027;s- <italic>t</italic>-test). The asterisk represents statistically significant difference between the unexposed control and the <italic>L. infantum</italic>-challenged group. <bold>(B)</bold> Gating strategy showing neutrophil region (FSC vs. SSC) with or without <italic>L. infantum</italic> infection (labeled with CellTracker) expressing TREM-1. The dotted line represents the negative cells for TREM-1. <bold>(C)</bold> Neutrophils from healthy donors were exposed to <italic>L. infantum</italic> labeled with CellTracker at a 5:1 ratio (parasites:cell) for 30 min and 3 h. Frequency of neutrophils expressing TREM-1 and MFI was assessed. Bars represent the mean &#x000B1; standard error of 2 independent experiments with 5 donors (30 min) and 6 donors (3 h) (<sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05, <sup>&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.01, by Student&#x00027;s- <italic>t</italic>-test). <bold>(D)</bold> Neutrophils from healthy donors were exposed to <italic>L. infantum</italic> at a 5:1 ratio (parasites:cell). After 30 min and 3 h, release of sTREM-1 by neutrophils into the culture supernatants were measured by ELISA. Bars represent the mean &#x000B1; standard error of 2 independent experiments with 5 donors performed in triplicate (<sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05, by Student&#x00027;s- <italic>t</italic>-test). <bold>(E)</bold> Neutrophils from healthy donors were exposed to <italic>L. infantum</italic> at a 1:1, 5:1, and 10:1 ratio (parasites:cell). After for 3, 6, and 9 h, release of sTREM-1 by neutrophils into the culture supernatants were measured by ELISA. Bars represent the mean &#x000B1; standard error of 2 independent experiments with 5 donors performed in triplicate (<sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05; <sup>&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.01, by Friedman test with Bonferroni post-test). The asterisk represents statistically significant difference between the unexposed control and the <italic>L. infantum</italic>-challenged groups.</p></caption>
<graphic xlink:href="fmicb-08-02265-g0002.tif"/>
</fig>
</sec>
<sec>
<title><italic>Leishmania infantum</italic> induces release of TREM-1 on neutrophils</title>
<p>Next, we evaluated whether neutrophil surface expression of TREM-1 could be a source of sTREM-1 after <italic>L. infantum</italic> exposure (Figures <xref ref-type="fig" rid="F2">2B,C</xref>). The unexposed group served as internal controls and showed highest frequency and MFI of membrane-bound TREM-1 expression compared to neutrophils infected by <italic>L. infantum</italic> (Leish<sup>&#x0002B;</sup> population) at both 30 min and 3 h post-exposure. Leish<sup>&#x0002B;</sup> population had lower frequency and MFI of TREM-1 expression compared to the exposed neutrophils, but not infected (Leish<sup>&#x02212;</sup> population) at 30 min post-exposure. In addition, the Leish<sup>&#x02212;</sup> population also showed lower frequency and MFI of membrane-bound TREM-1 expression on neutrophils after 3 h, compared to unexposed neutrophils.</p>
<p>To corroborate our findings that high levels of serum sTREM-1 are associated with VL severity, we evaluated the presence of sTREM-1 released in the culture supernatant of peripheral-blood neutrophils infection with leishmania (Figure <xref ref-type="fig" rid="F2">2D</xref>). Although there was no statistical difference at 30 min of exposure, we observed a slightly increased release of sTREM-1 in the neutrophil exposed to <italic>L. infantum</italic> at a rate of 5:1 (parasites: neutrophils), when compared to the unexposed group. However, at 3 h of exposure, the levels of sTREM-1 in exposed neutrophils were 2.67-fold higher than in the unexposed neutrophils group (<italic>p</italic> &#x0003D; 0.0313). In addition, we assessed whether release of sTREM-1 by neutrophils was associated with increased number and time of <italic>L. infantum</italic> challenge (Figure <xref ref-type="fig" rid="F2">2E</xref>). For this, neutrophils were exposed to <italic>L. infantum</italic> at a rate of 1:1, 5:1, and 10:1 parasites to neutrophils, respectively, for 3, 6, and 9 h. Results revealed a direct correlation between increased parasite load and exposure time with sTREM-1 release. Taken together, this study shows that <italic>L. infantum</italic> exposure enhances the transcription of TREM-1 and molecules associated to its activation, as well as release of sTREM-1 from neutrophils.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In VL, high serum levels of cytokines play an important role in pathogenesis and can be associated with clinical disease manifestations that may lead to death (Santos et al., <xref ref-type="bibr" rid="B24">2016</xref>; Silva et al., <xref ref-type="bibr" rid="B25">2017</xref>). This is the first report to show that high serum levels of sTREM-1 in patients correlate with severe disease outcomes. We also demonstrate that <italic>in vitro L. infantum</italic> exposure upregulates TREM-1, DAP12, and IL-8 gene expression in neutrophils, while reducing expression of membrane-bound TREM-1 and inducing release of sTREM-1 in the supernatant.</p>
<p>We observed that all SVL patients who died presented high serum level of sTREM-1. Furthermore, there was a correlation between sTREM-1 and clinical markers of disease, such as positive correlation with liver size and negative correlations with both leukocyte count and hemoglobin concentration. Hematological changes are constant in VL, and in untreated cases, patients die due to excessive bleeding, severe anemia, and bacterial infections (Sampaio et al., <xref ref-type="bibr" rid="B23">2010</xref>). In hemodialysis patients, sTREM-1 levels were significantly increased, whereas a negative correlation between hemoglobin concentration and sTREM-1 level was observed (Essa and Elzorkany, <xref ref-type="bibr" rid="B10">2015</xref>). This suggests sTREM-1, together with other clinical and laboratorial parameters can, serve as a novel and valuable biomarker for severity in VL.</p>
<p>sTREM-1 has been also described as an important predictor and diagnostic marker for other infections (Gibot and Cravoisy, <xref ref-type="bibr" rid="B11">2004</xref>). For instance, it was reported that sTREM-1 is valuable for differentiating sepsis from SIRS (Gibot et al., <xref ref-type="bibr" rid="B14">2004c</xref>; Richeldi et al., <xref ref-type="bibr" rid="B20">2004</xref>; Siranovi&#x00107; et al., <xref ref-type="bibr" rid="B26">2011</xref>). Moreover, sTREM-1 is described to be valuable for early diagnosis and severity of neonatal sepsis (Adly et al., <xref ref-type="bibr" rid="B1">2014</xref>; Ar&#x000ED;zaga-Ballesteros et al., <xref ref-type="bibr" rid="B2">2015</xref>; Saldir et al., <xref ref-type="bibr" rid="B22">2015</xref>). However, a systematic review and meta-analysis shows that sTREM-1 had a moderate diagnostic performance in differentiating sepsis from SIRS in adult patients (Wu et al., <xref ref-type="bibr" rid="B28">2012</xref>). Additionally, sTREM-1 alone is insufficient as a biomarker to predict mortality (Su et al., <xref ref-type="bibr" rid="B27">2016</xref>).</p>
<p>Interestingly, we demonstrated that the exposure to <italic>L. infantum</italic> increased TREM-1, DAP12, and IL-18 gene expression in neutrophils. In bacterial infections, lipopolysaccharide from bacteria induces TREM-1 expression in neutrophils (Ramanathan et al., <xref ref-type="bibr" rid="B19">2005</xref>). However, the specific ligand(s) for TREM-1 in <italic>Leishmania</italic> are unknown, thus warranting further investigations. Carneiro et al. found that high INF&#x003B3;-producing individuals expressed genes associated with pathways related to TREM-1 signaling (Carneiro et al., <xref ref-type="bibr" rid="B7">2016</xref>). In this case, the involvement of TREM-1 preferentially in high INF&#x003B3;-producing individuals suggests that a stronger <italic>Leishmania</italic> response may be involved in tissue destruction and lesion development (Carneiro et al., <xref ref-type="bibr" rid="B7">2016</xref>).</p>
<p>Neutrophil exposure to <italic>L. infantum</italic> reduced surface TREM-1 expression and increased sTREM-1 levels. Previous studies have reported that patients with sepsis had increased sTREM-1 and decreased membrane-bound TREM-1 expression on neutrophils compared to non-infectious systemic inflammatory response syndrome (Oku et al., <xref ref-type="bibr" rid="B18">2013</xref>). Although we showed an increase in the TREM-1 gene expression, the elevated levels were not found on the neutrophil surface. This may be due to either TREM-1 surface shedding and/or alternative splicing (Baruah et al., <xref ref-type="bibr" rid="B4">2015</xref>). In this study, we demonstrated increased release of sTREM-1 after <italic>L. infantum</italic> infection in a dose-response and time course effect. These results suggest that neutrophils are a major source of sTREM-1 in VL.</p>
<p>TREM-1 surface shedding may occur either by the action of neutrophil proteinases or proteases released by <italic>Leishmania</italic> (Mottram et al., <xref ref-type="bibr" rid="B17">2004</xref>). Alternatively, it is possible that the presence of <italic>Leishmania</italic> induces the release of TREM-1 present in granules by alternative splicing (Baruah et al., <xref ref-type="bibr" rid="B4">2015</xref>). One of the main pathways of recognition of <italic>Leishmania</italic> is the TLR2 pathway. Pathogen recognition by this pathway has been shown to induce expression of TREM-1 (Arts et al., <xref ref-type="bibr" rid="B3">2013</xref>). Recently, Sacramento et al. (<xref ref-type="bibr" rid="B21">2017</xref>) showed that during <italic>L. infantum</italic> infection, TLR2 signaling has a direct effect on neutrophils, mediating their activation, NO and TNF production and <italic>L. infantum</italic> uptake. These results demonstrate that TLR2 signaling plays an important role in immune protection against <italic>L. infantum</italic> infection (Sacramento et al., <xref ref-type="bibr" rid="B21">2017</xref>). Thus, reduction of TREM-1 on the surface of neutrophils may favor the establishment of the parasite, since signaling is important for the activation of microbicide mechanisms and induction of pro-inflammatory cytokines. Yizengaw et al. (<xref ref-type="bibr" rid="B29">2016</xref>) reported that neutrophils from patients with VL are highly activated. However, these patients also have an increased frequency of immature neutrophils that have impaired effector function, degranulation events, ROS production and phagocytic abilities (Yizengaw et al., <xref ref-type="bibr" rid="B29">2016</xref>). These authors suggest that these dysfunctional neutrophils play a role in the systemic inflammatory response characteristic of VL patients and contribute to disease severity.</p>
<p>As sTREM-1 negatively regulate TREM-1 receptor signaling via ligand neutralization (Klesney-Tait et al., <xref ref-type="bibr" rid="B15">2006</xref>), the increased sTREM-1 levels observed in severe VL, in which an exaggerated inflammatory response is observed, may be an attempt to restrain excessive inflammation in VL. This response could be largely beneficial to the patient. However, in the present study, high levels of sTREM-1 is associated with clinical parameters of disease severity. Additionally, our data show that leishmania is activating TREM-1 transcription and release of sTREM-1 from the neutrophils. Therefore, it is possible that the release of sTREM-1 induced by leishmania inhibits the inflammatory pathway and contributes to the disease by impairing TREM-1 receptor signaling.</p>
</sec>
<sec id="s5">
<title>Author contributions</title>
<p>Conceived and designed the experiments: LB, VB, AJ, RA, and TdM. Follow-up of patients: AS and RA. Performed the experiments: LB, LM, MS-F, NP, CC, and TdM. Analyzed the data: LB, NP, CC, DT, ML, VB, AJ, RA, and TdM. Contributed reagents/materials/analysis tools: ML, VB, AJ, RA, and TdM. Wrote the manuscript: LB, NP, ML, AJ, and TdM.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack><p>We thank to the Pediatric and Infectious Disease Clinic Group from the University Hospital, Universidade Federal de Sergipe.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adly</surname> <given-names>A. A. M.</given-names></name> <name><surname>Ismail</surname> <given-names>E. A.</given-names></name> <name><surname>Andrawes</surname> <given-names>N. G.</given-names></name> <name><surname>El-Saadany</surname> <given-names>M. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis</article-title>. <source>Cytokine</source> <volume>65</volume>, <fpage>184</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2013.11.004</pub-id><pub-id pub-id-type="pmid">24290866</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ar&#x000ED;zaga-Ballesteros</surname> <given-names>V.</given-names></name> <name><surname>Alcorta-Garc&#x000ED;a</surname> <given-names>M. R.</given-names></name> <name><surname>L&#x000E1;zaro-Mart&#x000ED;nez</surname> <given-names>L. C.</given-names></name> <name><surname>Alan&#x000ED;s-Cajero</surname> <given-names>J. M.</given-names></name> <name><surname>Villela</surname> <given-names>L.</given-names></name> <name><surname>Castorena-Torres</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Can sTREM-1 predict septic shock &#x00026; death in late-onset neonatal sepsis? A pilot study</article-title>. <source>Int. J. Infect. Dis.</source> <volume>30</volume>, <fpage>27</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.10.013</pub-id><pub-id pub-id-type="pmid">25461656</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname> <given-names>R. J. W.</given-names></name> <name><surname>Joosten</surname> <given-names>L. A. B.</given-names></name> <name><surname>Meer</surname> <given-names>J. W. M.</given-names></name> <name><surname>van der Meer</surname> <given-names>J. W.</given-names></name> <name><surname>Netea</surname> <given-names>M. G.</given-names></name></person-group> (<year>2013</year>). <article-title>TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors</article-title>. <source>J. Leukoc. Biol.</source> <volume>93</volume>, <fpage>209</fpage>&#x02013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0312145</pub-id><pub-id pub-id-type="pmid">23108097</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baruah</surname> <given-names>S.</given-names></name> <name><surname>Keck</surname> <given-names>K.</given-names></name> <name><surname>Vrenios</surname> <given-names>M.</given-names></name> <name><surname>Pope</surname> <given-names>M. R.</given-names></name> <name><surname>Pearl</surname> <given-names>M.</given-names></name> <name><surname>Doerschug</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Identification of a novel splice variant isoform of TREM-1 in human neutrophil granules</article-title>. <source>J. Immunol.</source> <volume>195</volume>, <fpage>5725</fpage>&#x02013;<lpage>5731</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1402713</pub-id><pub-id pub-id-type="pmid">26561551</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouchon</surname> <given-names>A.</given-names></name> <name><surname>Dietrich</surname> <given-names>J.</given-names></name> <name><surname>Colonna</surname> <given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes</article-title>. <source>J. Immunol.</source> <volume>164</volume>, <fpage>4991</fpage>&#x02013;<lpage>4995</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.164.10.4991</pub-id><pub-id pub-id-type="pmid">10799849</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>C.</given-names></name> <name><surname>Gu</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases</article-title>. <source>Front Med.</source> <volume>1</volume>, <fpage>169</fpage>&#x02013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1007/s11684-017-0505-z</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname> <given-names>M. W.</given-names></name> <name><surname>Fukutani</surname> <given-names>K. F.</given-names></name> <name><surname>Andrade</surname> <given-names>B. B.</given-names></name> <name><surname>Curvelo</surname> <given-names>R. P.</given-names></name> <name><surname>Cristal</surname> <given-names>J. R.</given-names></name> <name><surname>Carvalho</surname> <given-names>A. M.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Gene expression profile of high IFN-&#x003B3; Producers Stimulated with <italic>Leishmania braziliensis</italic> identifies genes associated with cutaneous leishmaniasis</article-title>. <source>PLoS Negl Trop Dis</source>. <volume>10</volume>:<fpage>e0005116</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005116</pub-id><pub-id pub-id-type="pmid">27870860</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>D. L.</given-names></name> <name><surname>Rocha</surname> <given-names>R. L.</given-names></name> <name><surname>Chaves</surname> <given-names>E. B.</given-names></name> <name><surname>Batista</surname> <given-names>V. G.</given-names></name> <name><surname>Costa</surname> <given-names>H. L.</given-names></name> <name><surname>Costa</surname> <given-names>C. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software</article-title>. <source>Rev. Soc. Bras. Med. Trop.</source> <volume>49</volume>, <fpage>728</fpage>&#x02013;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1590/0037-8682-0258-2016</pub-id><pub-id pub-id-type="pmid">28001220</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dagley</surname> <given-names>M. J.</given-names></name> <name><surname>Saunders</surname> <given-names>E. C.</given-names></name> <name><surname>Simpson</surname> <given-names>K. J.</given-names></name> <name><surname>McConville</surname> <given-names>M. J.</given-names></name></person-group> (<year>2015</year>). <article-title>High-content assay for measuring intracellular growth of Leishmania in human macrophages</article-title>. <source>Assay Drug Dev. Technol.</source> <volume>13</volume>, <fpage>389</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1089/adt.2015.652</pub-id><pub-id pub-id-type="pmid">26247370</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Essa</surname> <given-names>E. S.</given-names></name> <name><surname>Elzorkany</surname> <given-names>K. M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>sTREM-1 in patients with chronic kidney disease on hemodialysis</article-title>. <source>APMIS</source> <volume>123</volume>, <fpage>969</fpage>&#x02013;<lpage>974</lpage>. <pub-id pub-id-type="doi">10.1111/apm.12459</pub-id><pub-id pub-id-type="pmid">26495896</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname> <given-names>S.</given-names></name> <name><surname>Cravoisy</surname> <given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection</article-title>. <source>Clin. Med. Res</source>. <volume>2</volume>, <fpage>181</fpage>&#x02013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.3121/cmr.2.3.181</pub-id><pub-id pub-id-type="pmid">15931355</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname> <given-names>S.</given-names></name> <name><surname>Cravoisy</surname> <given-names>A.</given-names></name> <name><surname>Levy</surname> <given-names>B.</given-names></name> <name><surname>Bene</surname> <given-names>M.</given-names></name> <name><surname>Faure</surname> <given-names>G.</given-names></name> <name><surname>Bollaert</surname> <given-names>P.-E.</given-names></name></person-group> (<year>2004a</year>). <article-title>Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia</article-title>. <source>N. Engl. J. Med</source>. <volume>350</volume>, <fpage>451</fpage>&#x02013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa031544</pub-id><pub-id pub-id-type="pmid">14749453</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname> <given-names>S.</given-names></name> <name><surname>Kolopp-Sarda</surname> <given-names>M.-N.</given-names></name> <name><surname>B&#x000E9;n&#x000E9;</surname> <given-names>M.-C.</given-names></name> <name><surname>Bollaert</surname> <given-names>P. E.</given-names></name> <name><surname>Lozniewski</surname> <given-names>A.</given-names></name> <name><surname>Mory</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2004b</year>). <article-title>A Soluble form of the triggering receptor expressed on myeloid Cells-1 modulates the inflammatory response in Murine Sepsis</article-title>. <source>J. Exp. Med.</source> <volume>200</volume>, <fpage>1419</fpage>&#x02013;<lpage>1426</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20040708</pub-id><pub-id pub-id-type="pmid">15557347</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname> <given-names>S.</given-names></name> <name><surname>Kolopp-Sarda</surname> <given-names>M.-N.</given-names></name> <name><surname>B&#x000E9;n&#x000E9;</surname> <given-names>M. C.</given-names></name> <name><surname>Cravoisy</surname> <given-names>A.</given-names></name> <name><surname>Levy</surname> <given-names>B.</given-names></name> <name><surname>Faure</surname> <given-names>G. C.</given-names></name> <etal/></person-group>. (<year>2004c</year>). <article-title>Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis</article-title>. <source>Ann. Int. Med.</source> <volume>141</volume>, <fpage>9</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-141-1-200407060-00009</pub-id><pub-id pub-id-type="pmid">15238365</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klesney-Tait</surname> <given-names>J.</given-names></name> <name><surname>Turnbull</surname> <given-names>I. R.</given-names></name> <name><surname>Colonna</surname> <given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>The TREM receptor family and signal integration</article-title>. <source>Nat. Immunol.</source> <volume>7</volume>, <fpage>1266</fpage>&#x02013;<lpage>1273</lpage>. <pub-id pub-id-type="doi">10.1038/ni1411</pub-id><pub-id pub-id-type="pmid">17110943</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molad</surname> <given-names>Y.</given-names></name> <name><surname>Ofer-Shiber</surname> <given-names>S.</given-names></name> <name><surname>Pokroy-Shapira</surname> <given-names>E.</given-names></name> <name><surname>Oren</surname> <given-names>S.</given-names></name> <name><surname>Shay-Aharoni</surname> <given-names>H.</given-names></name> <name><surname>Babai</surname> <given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti- CCP-positive, early rheumatoid arthritis</article-title>. <source>Eur. J. Clin. Invest</source>. <volume>45</volume>, <fpage>557</fpage>&#x02013;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1111/eci.12442</pub-id><pub-id pub-id-type="pmid">25832796</pub-id></citation></ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mottram</surname> <given-names>J. C.</given-names></name> <name><surname>Coombs</surname> <given-names>G. H.</given-names></name> <name><surname>Alexander</surname> <given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Cysteine peptidases as virulence factors of Leishmania</article-title>. <source>Curr. Opin. Microbiol.</source> <volume>7</volume>, <fpage>375</fpage>&#x02013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2004.06.010</pub-id><pub-id pub-id-type="pmid">15358255</pub-id></citation></ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oku</surname> <given-names>R.</given-names></name> <name><surname>Oda</surname> <given-names>S.</given-names></name> <name><surname>Nakada</surname> <given-names>T.</given-names></name> <name><surname>Sadahiro</surname> <given-names>T.</given-names></name> <name><surname>Nakamura</surname> <given-names>M.</given-names></name> <name><surname>Hirayama</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS</article-title>. <source>Cytokine</source> <volume>61</volume>, <fpage>112</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2012.09.003</pub-id><pub-id pub-id-type="pmid">23046618</pub-id></citation></ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan</surname> <given-names>B.</given-names></name> <name><surname>Ernest Minton</surname> <given-names>J.</given-names></name> <name><surname>Ross</surname> <given-names>C. R.</given-names></name> <name><surname>Blecha</surname> <given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>Cloning of porcine triggering receptor expressed on myeloid cells-1 (TREM-1) and its induction by lipopolysaccharide, peptidoglycan, and <italic>Salmonella enterica</italic> serovar Typhimurium infection</article-title>. <source>Dev. Comp. Immunol.</source> <volume>29</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.dci.2004.05.007</pub-id><pub-id pub-id-type="pmid">15325519</pub-id></citation></ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname> <given-names>L.</given-names></name> <name><surname>Mariani</surname> <given-names>M.</given-names></name> <name><surname>Losi</surname> <given-names>M.</given-names></name> <name><surname>Maselli</surname> <given-names>F.</given-names></name> <name><surname>Corbetta</surname> <given-names>L.</given-names></name> <name><surname>Buonsanti</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Triggering receptor expressed on myeloid cells: Role in the diagnosis of lung infections</article-title>. <source>Eur. Respir J</source>. <volume>24</volume>, <fpage>247</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.04.00014204</pub-id><pub-id pub-id-type="pmid">15332392</pub-id></citation></ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacramento</surname> <given-names>L. A.</given-names></name> <name><surname>Costa</surname> <given-names>J. L.</given-names></name> <name><surname>da Lima</surname> <given-names>M. H. F.</given-names></name> <name><surname>Sampaio</surname> <given-names>P. A.</given-names></name> <name><surname>Almeida</surname> <given-names>R. P.</given-names></name> <name><surname>Cunha</surname> <given-names>F. Q.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Toll-like receptor 2 is required for inflammatory process development during <italic>Leishmania infantum</italic> infection</article-title>. <source>Front. Microbiol.</source> <volume>8</volume>:<fpage>262</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.00262</pub-id><pub-id pub-id-type="pmid">28280488</pub-id></citation></ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saldir</surname> <given-names>M.</given-names></name> <name><surname>Tunc</surname> <given-names>T.</given-names></name> <name><surname>Cekmez</surname> <given-names>F.</given-names></name> <name><surname>&#x000C7;etinkaya</surname> <given-names>M.</given-names></name> <name><surname>Kalayci</surname> <given-names>T.</given-names></name> <name><surname>Fidanci</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Endocan and soluble triggering receptor expressed on myeloid Cells-1 as novel markers for neonatal sepsis</article-title>. <source>Pediatr Neonatol.</source> <volume>56</volume>, <fpage>415</fpage>&#x02013;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1016/j.pedneo.2015.03.006</pub-id><pub-id pub-id-type="pmid">26341458</pub-id></citation></ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sampaio</surname> <given-names>M. J. A.</given-names></name> <name><surname>Cavalcanti</surname> <given-names>N. V.</given-names></name> <name><surname>Alves</surname> <given-names>J. G. B.</given-names></name> <name><surname>Fernandes Filho</surname> <given-names>M. J. C.</given-names></name> <name><surname>Correia</surname> <given-names>J. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Risk factors for death in children with visceral leishmaniasis</article-title>. <source>PLoS Negl. Trop. Dis</source>. <volume>4</volume>:<fpage>e877</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0000877</pub-id><pub-id pub-id-type="pmid">21072238</pub-id></citation></ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname> <given-names>P. L.</given-names></name> <name><surname>dos Oliveira</surname> <given-names>F. A.</given-names></name> <name><surname>de Santos</surname> <given-names>M. L. B.</given-names></name> <name><surname>Cunha</surname> <given-names>L. C.</given-names></name> <name><surname>Lino</surname> <given-names>M. T.</given-names></name> <name><surname>de Oliveira</surname> <given-names>M. F.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>The severity of visceral leishmaniasis correlates with elevated levels of serum IL-6, IL-27 and sCD14</article-title>. <source>PLoS Negl. Trop. Dis</source>. <volume>10</volume>, <fpage>1</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0004375</pub-id><pub-id pub-id-type="pmid">26814478</pub-id></citation></ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname> <given-names>R. L. L.</given-names></name> <name><surname>Santos</surname> <given-names>M. B.</given-names></name> <name><surname>Almeida</surname> <given-names>P. L. S.</given-names></name> <name><surname>Barros</surname> <given-names>T. S.</given-names></name> <name><surname>Magalh&#x000E3;es</surname> <given-names>L.</given-names></name> <name><surname>Cazzaniga</surname> <given-names>R. A.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasis</article-title>. <source>PLoS Negl. Trop. Dis</source>. <volume>11</volume>:<fpage>e0005486</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005486</pub-id><pub-id pub-id-type="pmid">28355218</pub-id></citation></ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siranovi&#x00107;</surname> <given-names>M.</given-names></name> <name><surname>Kovac</surname> <given-names>J.</given-names></name> <name><surname>Gopcevi&#x00107;</surname> <given-names>S.</given-names></name> <name><surname>Keleci&#x00107;</surname> <given-names>M.</given-names></name> <name><surname>Kovac</surname> <given-names>N.</given-names></name> <name><surname>Rode</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Human soluble TREM-1: lung and serum levels in patients with bacterial ventilator associated pneumonia</article-title>. <source>Acta Clin. Croat</source>. <volume>50</volume>, <fpage>345</fpage>&#x02013;<lpage>349</lpage>. <pub-id pub-id-type="pmid">22384768</pub-id></citation></ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>L.</given-names></name> <name><surname>Liu</surname> <given-names>D.</given-names></name> <name><surname>Chai</surname> <given-names>W.</given-names></name> <name><surname>Liu</surname> <given-names>D.</given-names></name> <name><surname>Long</surname> <given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source> <volume>6</volume>:<fpage>e010314</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-010314</pub-id><pub-id pub-id-type="pmid">27178971</pub-id></citation></ref>
<ref id="B28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>F.</given-names></name> <name><surname>Fan</surname> <given-names>X.</given-names></name> <name><surname>Bao</surname> <given-names>R.</given-names></name> <name><surname>Bo</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis</article-title>. <source>Crit. Care</source> <volume>16</volume>:<fpage>R229</fpage>. <pub-id pub-id-type="doi">10.1186/cc11884</pub-id><pub-id pub-id-type="pmid">23194114</pub-id></citation></ref>
<ref id="B29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yizengaw</surname> <given-names>E.</given-names></name> <name><surname>Getahun</surname> <given-names>M.</given-names></name> <name><surname>Tajebe</surname> <given-names>F.</given-names></name> <name><surname>Cervera</surname> <given-names>E. C.</given-names></name> <name><surname>Adem</surname> <given-names>E.</given-names></name> <name><surname>Mesfin</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Visceral leishmaniasis patients display altered composition and maturity of neutrophils as well as impaired neutrophil effector functions</article-title>. <source>Front. Immunol</source>. <volume>7</volume>:<fpage>517</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00517</pub-id><pub-id pub-id-type="pmid">27965662</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by grants: Conselho Nacional de Desenvolvimento Cient&#x000ED;fico e Tecnol&#x000F3;gico (CNPq), MCTI/CNPQ/Universal 14/2014&#x02014;460743/2014-7 (TdM) and PROCAD/CASADINHO&#x02014;n&#x000B0;552721/2011-5 (RA); Funda&#x000E7;&#x000E3;o de Apoio &#x000E0; Pesquisa e &#x000E0; Inova&#x000E7;&#x000E3;o Tecnol&#x000F3;gica do Estado de Sergipe FAPITEC/SE/FUNTEC/CNPq n&#x000B0;12/2009&#x02014;019.203.02712/2009-8 (AJ); Coordena&#x000E7;&#x000E3;o de Aperfei&#x000E7;oamento de Pessoal de N&#x000ED;vel Superior (CAPES), Programa Nacional de Incentivo &#x000E0; Pesquisa em Parasitologia B&#x000E1;sica, Edital No 032/2010 (AJ); National Institute Health, NIH Grant&#x00023; SC2GM103741 (ML); Department of Defense, DOD Grant&#x00023; W911NF-14-1-0123, (ML); and National Science Foundation, NSF Grant&#x00023; 1428768, (ML).</p>
</fn>
</fn-group>
</back>
</article>